Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of BN104 in relapsed/refractory acute leukemia
CTR20232750Phase 2Active
- Sponsor
- Duality Biotherapeutics
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BN104 in Acute Leukaemia, sponsored by Duality Biotherapeutics. Started Oct 2023; status: active.
02
Drugs
BN104
03
Conditions
Acute Leukaemia
Beyond the preview
Go deeper on CTR20232750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232750.